4-month moxifloxacin containing regimens in the treatment of patients with sputum-positive pulmonary tuberculosis in South India - a randomised clinical trial
- 1 April 2020
- journal article
- research article
- Published by Wiley in Tropical Medicine & International Health
- Vol. 25 (4) , 483-495
Abstract
Background Shortening tuberculosis (TB) treatment duration is a research priority. We tested the efficacy and safety of 3- and 4-month regimens containing moxifloxacin in a randomised clinical trial in pulmonary TB (PTB) patients in South India. Methods New, sputum-positive, adult, HIV-negative, non-diabetic PTB patients were randomised to 3- or 4-month moxifloxacin regimens [moxifloxacin (M), isoniazid (H), rifampicin (R), pyrazinamide (Z) and ethambutol (E)] or to a control regimen (2H(3)R(3)Z(3)E(3)/4R(3)H(3)) [C]. The 4 test regimens were 3R(7)H(7)Z(7)E(7)M(7) [M3], 2R(7)H(7)Z(7)E(7)M(7)/2R(7)H(7)M(7) [M4], 2R(7)H(7)Z(7)E(7)M(7)/2R(3)H(3)M(3) [M4-I] or 2R(7)H(7)Z(7)E(7)M(7)/2R(3)H(3)E(3)M(3) [M4-IE]. Treatment was directly observed. Clinical and bacteriological assessments were done monthly during treatment and for 24 months post-treatment. The primary end point was TB recurrence post-treatment. Results Of 1371 patients, randomised, modified intention-to-treat (ITT) analysis was done in 1329 and per-protocol (PP) analysis in 1223 patients. Regimen M3 was terminated due to high TB recurrence rates. 'Favourable' response at end of treatment was 96-100% in the moxifloxacin regimens and 93% in the control regimen. Among these, the TB recurrence occurred in 4.1% in the M4 regimen and in 4.5% in the control regimen and demonstrated equivalence within a 5% margin (95% CI -3.68, 4.55). Similar findings were observed in modified ITT analysis. The TB recurrence rates in the M4-I and M4-IE regimens did not show equivalence with the control regimen. Sixteen (1.4%) of 1087 patients in the moxifloxacin regimens required treatment modification. Conclusion The 4-month daily moxifloxacin regimen [M4] was found to be equivalent and as safe as the 6-month thrice-weekly control regimen.Keywords
Funding Information
- Indian Council of Medical Research
This publication has 14 references indexed in Scilit:
- High-Dose Rifapentine with Moxifloxacin for Pulmonary TuberculosisNew England Journal of Medicine, 2014
- Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive TuberculosisNew England Journal of Medicine, 2014
- Sputum Culture Conversion With Moxifloxacin-Containing Regimens in the Treatment of Patients With Newly Diagnosed Sputum-Positive Pulmonary Tuberculosis in South IndiaClinical Infectious Diseases, 2014
- Randomized Clinical Trial of Thrice-Weekly 4-Month Moxifloxacin or Gatifloxacin Containing Regimens in the Treatment of New Sputum Positive Pulmonary Tuberculosis PatientsPLOS ONE, 2013
- Bactericidal Activity of Moxifloxacin on Exponential and Stationary Phase Cultures ofMycobacterium tuberculosisJournal of Chemotherapy, 2009
- Moxifloxacin-containing Regimens of Reduced Duration Produce a Stable Cure in Murine TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2004
- Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2004
- Sterilizing Activities of Fluoroquinolones against Rifampin-Tolerant Populations of Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2003
- In Vitro and In Vivo Activities of Moxifloxacin and Clinafloxacin against Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 1998
- Comparison of various measures of sensitivity of M. tuberculosis to ethambutolTubercle, 1978